## TEM: Tempus AI, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.9% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($65.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $85 | $80 | +6% |
| 2025-11-25 | BTIG | $105 | $96 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-25 | BTIG | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 5.7% (+106.8%)
- BAILLIE GIFFORD & CO: 5.6% (-19.9%)
- Vanguard Group Inc: 5.5% (+22.1%)
- ARK Investment Manag: 4.2% (-3.3%)
- Blackrock Inc.: 3.9% (+62.8%)

### Key Risks

1. High beta (2.84) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. High short interest (15.1%, 3.3 days to cover): squeeze risk or crowded bearish bet.
3. Near-term weakness: 9.5% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.49 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.3x). Revenue growth strong at 25% YoY. Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.1B |
| Beta | 1.00 |
| 52W Range | $31.36 - $104.32 |
| Short Interest | 15.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.49 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 3.8% to -0.9% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). MACD histogram positive (0.62), confirming momentum. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.94% (CS: 40) | Neutral |
| RSI_14 | 45.1 | Neutral |
| MACD Histogram | 0.62 | Bullish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 0.905x | Below |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $73.86
- **Stop Loss:** $65.90 (10.8% risk)
- **Target:** $81.82 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 173
- **Position Value:** $12,777.78
- **Portfolio %:** 12.78%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-24 (Est: $-0.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.18 | $-0.11 | +37.3% |
| 2025Q2 | $-0.25 | $-0.22 | +13.0% |
| 2025Q1 | $-0.27 | $-0.24 | +10.2% |
| 2024Q4 | $-0.15 | $-0.18 | -17.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*